Posted by Michael Wonder on 22 Mar 2022
KYE Pharmaceuticals files Accrufer new drug submission in Canada for the treatment of iron deficiency
21 March 2022 - Shield Therapeutics announces that KYE Pharmaceuticals has submitted a new drug submission to Health Canada for the regulatory review and approval of Accrufer.
If approved, Accrufer would be the first prescription only oral iron therapy approved by Health Canada. Marketing approval for Accrufer is expected to be during first half of 2023.
